Ropes & Gray represented TRex Bio in an oversubscribed $50 million financing. The financing included funding from new investors Janus Henderson Investors, Balyasny Asset Management and Affinity Asset Advisors, as well as existing investors Alexandria Venture Investments, Avego BioScience Capital, Delos Capital, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Inc, Pfizer Ventures, Polaris Partners and SV Health Investors. The deal was announced in a January 27 press release.
TRex Bio is a clinical-stage biotechnology company discovering and developing immunoregulatory medicines based on tissue Treg biology. Proceeds from the latest financing will be used to further the company’s pipeline of clinical and preclinical programs.
The Ropes & Gray team was led by emerging companies & venture capital partner Rajarshi Banerjee.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.